Dec 03, 2007 - EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced that it has completed patient enrollment in the Phase IIb "Neuracept" trial for EpiCept(TM) NP-1 cream. EpiCept NP-1 is a patented topical cream formulation of two FDA- approved drugs, 4% amitriptyline and 2% ketamine, and is intended to provide long-term relief from the pain of peripheral neuropathies... EpiCept 's Press Release -
Monday, December 3, 2007
Phase IIb Trial of EpiCept NP-1 in Diabetic Peripheral Neuropathy
Dec 03, 2007 - EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced that it has completed patient enrollment in the Phase IIb "Neuracept" trial for EpiCept(TM) NP-1 cream. EpiCept NP-1 is a patented topical cream formulation of two FDA- approved drugs, 4% amitriptyline and 2% ketamine, and is intended to provide long-term relief from the pain of peripheral neuropathies... EpiCept 's Press Release -
